SELLAS Life Sciences Group, Inc.
SLS
$6.32
$1.1020.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.15M | 12.31M | 12.41M | 11.84M | 13.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.17M | 28.04M | 28.28M | 29.03M | 32.61M |
| Operating Income | -27.17M | -28.04M | -28.28M | -29.03M | -32.61M |
| Income Before Tax | -26.86M | -25.94M | -26.26M | -27.13M | -30.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.86 | -25.94 | -26.26 | -27.13 | -30.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.86M | -25.94M | -26.26M | -27.13M | -30.88M |
| EBIT | -27.17M | -28.04M | -28.28M | -29.03M | -32.61M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.25 | -0.29 | -0.33 | -0.39 | -0.54 |
| Normalized Basic EPS | -0.15 | -0.19 | -0.21 | -0.25 | -0.35 |
| EPS Diluted | -0.25 | -0.29 | -0.33 | -0.39 | -0.54 |
| Normalized Diluted EPS | -0.15 | -0.19 | -0.21 | -0.25 | -0.35 |
| Average Basic Shares Outstanding | 435.98M | 368.70M | 328.56M | 287.63M | 244.69M |
| Average Diluted Shares Outstanding | 435.98M | 368.70M | 328.56M | 287.63M | 244.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |